【摘要】：伴隨著醫(yī)改的不斷深入,政府出臺(tái)各項(xiàng)醫(yī)改政策全面調(diào)控藥品價(jià)格,使得本就毛利率低下的醫(yī)藥流通行業(yè)雪上加霜,而筆者所在的G醫(yī)藥流通公司位于民營經(jīng)濟(jì)發(fā)達(dá)浙江,醫(yī)藥流通市場(chǎng)競(jìng)爭(zhēng)激烈。在醫(yī)改不斷持續(xù)深入的情況下,在醫(yī)藥招標(biāo)、采購商和供應(yīng)商不斷降價(jià)、醫(yī)院不斷二次議價(jià)的情況下,再加上醫(yī)藥電商的爆發(fā)增長,企業(yè)市場(chǎng)銷售額增速已經(jīng)乏力,盈利空間進(jìn)一步被壓縮。怎么在行業(yè)創(chuàng)新升級(jí)的大環(huán)境中,做出適應(yīng)G醫(yī)藥流通公司的發(fā)展戰(zhàn)略,發(fā)展自己并且趕超競(jìng)爭(zhēng)對(duì)手,使G醫(yī)藥流通公司保持浙江區(qū)域行業(yè)領(lǐng)先的地位,是本文研究的主旨。本文以G醫(yī)藥流通公司的戰(zhàn)略管理所涉及的相關(guān)問題作為研究對(duì)象,通過一系列的訪談等方式,對(duì)G醫(yī)藥流通公司進(jìn)行了廣泛而深入的調(diào)研。故全文共分六部分：第一部分介紹了研究背景然后做了相關(guān)的文獻(xiàn)綜述,最后提出了論文的研究框架；第二部分介紹了公司的發(fā)展現(xiàn)狀及困境；第三部分是相關(guān)外部環(huán)境分析,利用了PEST模型和波特五力競(jìng)爭(zhēng)模型,對(duì)G醫(yī)藥流通公司的競(jìng)爭(zhēng)現(xiàn)狀進(jìn)行了分析；第四部分為G公司內(nèi)部資源和能力分析,并利用SWOT分析,最終導(dǎo)出了G公司的發(fā)展戰(zhàn)略；第五部分是G醫(yī)藥流通公司發(fā)展戰(zhàn)略的選擇、實(shí)施保障和實(shí)施效果評(píng)價(jià)；第六部分為總結(jié)及展望。本文針主要?jiǎng)?chuàng)新點(diǎn)是對(duì)G醫(yī)藥流通公司在互聯(lián)網(wǎng)興起的時(shí)代,充分分析企業(yè)自身優(yōu)勢(shì)與劣勢(shì),機(jī)遇與威脅,結(jié)合自身特點(diǎn),制定出適合自己的差異化戰(zhàn)略,打造出自己的區(qū)域競(jìng)爭(zhēng)優(yōu)勢(shì)。
[Abstract]:With the deepening of medical reform, the government has introduced various medical reform policies to comprehensively regulate drug prices, which makes the pharmaceutical circulation industry with low gross profit rate worse, and the G pharmaceutical circulation company in which the author is located in Zhejiang Province, where the private economy is developed. There is fierce competition in the pharmaceutical circulation market. Under the condition of continuous deepening of the medical reform, under the circumstances of the pharmaceutical bidding, the constant reduction of prices by buyers and suppliers, and the repeated renegotiation of prices by hospitals, and the explosion of e-commerce companies, the growth rate of sales in the enterprise market has become weak. Profit space is further compressed. How to adapt to the development strategy of G pharmaceutical circulation company in the environment of industry innovation and upgrade, to develop itself and catch up with its competitors, and to make G pharmaceutical circulation company keep the leading position of Zhejiang regional industry is the main purpose of this paper. This paper takes the strategic management of G Pharmaceutical Circulation Company as the research object, through a series of interviews and other methods, carries on the extensive and thorough investigation to the G Medicine Circulation Company. Therefore, the paper is divided into six parts: the first part introduces the research background and then makes a related literature review, and finally puts forward the research framework of the paper; the second part introduces the current situation and difficulties of the company; the third part is the analysis of the related external environment. By using PEST model and Porter's five forces competition model, the paper analyzes the current situation of G pharmaceutical circulation company, the fourth part is the analysis of the internal resources and capability of G company, and the development strategy of G company is derived by using SWOT analysis. The fifth part is the choice of the development strategy, the implementation guarantee and the implementation effect evaluation of G Pharmaceutical Circulation Company, the sixth part is the summary and prospect. The main innovation point of this paper is to analyze the advantages and disadvantages, opportunities and threats of the company in the era of the rise of the Internet, and to formulate a strategy of differentiation suitable for itself in combination with its own characteristics. To create their own regional competitive advantage.
【學(xué)位授予單位】：華東理工大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：F426.72;F252

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 譚曉林;孫太清;王超;楊芳;;價(jià)值創(chuàng)新:電子商務(wù)模式創(chuàng)新的關(guān)鍵[J];合作經(jīng)濟(jì)與科技;2015年20期

2 董華華;;互聯(lián)網(wǎng)金融“攪局”下的“鲇魚效應(yīng)”與價(jià)值創(chuàng)新[J];中國管理信息化;2015年13期

3 韓璐;;平安的“三網(wǎng)”合一新型醫(yī)療[J];二十一世紀(jì)商業(yè)評(píng)論;2015年07期

4 賈佳;王樹X ;劉媛;;“互聯(lián)網(wǎng)+醫(yī)藥企業(yè)”發(fā)展戰(zhàn)略[J];中外企業(yè)家;2015年18期

5 黃丹莉;;淺析供應(yīng)鏈環(huán)境下醫(yī)藥商業(yè)企業(yè)的發(fā)展對(duì)策——以九州通醫(yī)藥集團(tuán)為例[J];物流工程與管理;2015年05期

6 朱竟;景浩;;新醫(yī)改下民營醫(yī)藥商業(yè)企業(yè)的未來之路[J];遼寧中醫(yī)藥大學(xué)學(xué)報(bào);2015年04期

7 劉南;段璐璐;干華棟;;基于行業(yè)價(jià)值鏈模型分析的我國醫(yī)藥流通行業(yè)發(fā)展對(duì)策研究[J];現(xiàn)代管理科學(xué);2013年10期

8 張德書;戈文魯;;我國藥品生產(chǎn)流通市場(chǎng)現(xiàn)況分析[J];中國衛(wèi)生質(zhì)量管理;2011年05期

9 連華慶;;淺析我國醫(yī)藥流通行業(yè)發(fā)展策略[J];商業(yè)經(jīng)濟(jì);2011年12期

10 趙可;;淺析我國藥品流通的現(xiàn)狀及發(fā)展[J];中國商貿(mào);2011年06期

相關(guān)碩士學(xué)位論文 前4條

1 程萌;T醫(yī)藥公司發(fā)展戰(zhàn)略研究[D];北京交通大學(xué);2011年

2 李克俊;湖南九芝堂醫(yī)藥有限公司競(jìng)爭(zhēng)戰(zhàn)略研究[D];湖南大學(xué);2009年

3 李江;M醫(yī)藥流通公司發(fā)展戰(zhàn)略研究[D];北京交通大學(xué);2007年

4 石正軍;哈藥集團(tuán)發(fā)展戰(zhàn)略研究[D];哈爾濱工程大學(xué);2007年

，

本文編號(hào)：2266695